← Leaderboards
Anil K Sood
University Of Tx Md Anderson Can Ctr
$29,572,737
Attributed
$45,338,197
Total exposure
28
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$72,504,575 · 31
By mechanism
P50$22,369,036 · 12
R01$15,209,977 · 6
U54$14,649,653 · 3
T32$6,944,265 · 1
R35$5,030,879 · 1
UH3$3,158,668 · 1
Top collaborators
- Gabriel Lopez-Berestein16 shared
- Vahid Afshar-Kharghan13 shared
- Karen Hsieh Lu13 shared
- Robert C Bast11 shared
- George A. Calin8 shared
- Mauro Ferrari8 shared
- David G. Gorenstein7 shared
- Jennifer L West6 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ruy Lopez Ridaura$1,748,418
- Sara Lynn Loupot Thrower$58,612
- Robert Louis Coleman$722,405
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryTumorMalignant NeoplasmsCancer PatientCancer CellBaseIn VivoGrowthMouse ModelSignal TransductionResponseOvarianDesignNeoplasm MetastasisTumor GrowthWomanMediatingCancer CenterChemotherapyAffectBlood VesselsIn VitroResistanceRecurrence
Grant awards (140)
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$1,993,287
P50 · FY2025 · CA · contact PI
Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer$697,317
R01 · FY2025 · CA
Training of Academic Gynecologic Oncologists$515,659
T32 · FY2025 · CA · contact PI
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$441,654
R01 · FY2025 · CA
Targeting EGFL6 in Ovarian Cancer$273,109
P50 · FY2025 · CA · contact PI
Administrative Core$232,129
P50 · FY2025 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$177,085
P50 · FY2025 · CA · contact PI
08 Gynecological Cancers$24,691
P30 · FY2025 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$2,197,314
P50 · FY2024 · CA · contact PI
Training of Academic Gynecologic Oncologists$587,271
T32 · FY2024 · CA · contact PI
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$419,571
R01 · FY2024 · CA
Targeting EGFL6 in Ovarian Cancer$319,497
P50 · FY2024 · CA · contact PI
Administrative Core$270,025
P50 · FY2024 · CA · contact PI
Targeting EGFL6 in Ovarian Cancer$204,372
P50 · FY2024 · CA · contact PI
Targeting uterine serous carcinoma with antibody-drug conjugates$204,372
P50 · FY2024 · CA · contact PI
The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer$177,085
P50 · FY2024 · CA · contact PI
08 Gynecological Cancers$23,220
P30 · FY2024 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$2,144,148
P50 · FY2023 · CA · contact PI
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$634,124
R01 · FY2023 · CA
Training of Academic Gynecologic Oncologists$561,727
T32 · FY2023 · CA
Platelets promote growth of ovarian cancer$479,382
R01 · FY2023 · CA
Harnessing the power of exosomes for non-coding RNA delivery$436,053
R35 · FY2023 · CA · contact PI
Targeting EGFL6 in Ovarian Cancer$306,593
P50 · FY2023 · CA · contact PI
Administrative Core$260,586
P50 · FY2023 · CA · contact PI
Harnessing the power of exosomes for non-coding RNA delivery$895,013
R35 · FY2022 · CA · contact PI
Training of Academic Gynecologic Oncologists$547,824
T32 · FY2022 · CA
Platelets promote growth of ovarian cancer$479,382
R01 · FY2022 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$462,390
R01 · FY2022 · CA
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,686,672
P50 · FY2021 · CA
Harnessing the power of exosomes for non-coding RNA delivery$680,538
R35 · FY2021 · CA · contact PI
Platelets promote growth of ovarian cancer$489,165
R01 · FY2021 · CA
Training of Academic Gynecologic Oncologists$471,936
T32 · FY2021 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$471,827
R01 · FY2021 · CA
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer$344,532
P50 · FY2021 · CA · contact PI
Career Enhancement Program$74,398
P50 · FY2021 · CA · contact PI
Developmental Research Program$74,398
P50 · FY2021 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,722,942
P50 · FY2020 · CA
Harnessing the power of exosomes for non-coding RNA delivery$775,509
R35 · FY2020 · CA · contact PI
Platelets promote growth of ovarian cancer$489,165
R01 · FY2020 · CA
Training of Academic Gynecologic Oncologists$475,582
T32 · FY2020 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$471,827
R01 · FY2020 · CA
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer$359,129
P50 · FY2020 · CA · contact PI
P3: EphA2 Targeting in Uterine Carcinoma$302,812
P50 · FY2020 · CA · contact PI
P3: EphA2 Targeting in Uterine Carcinoma$162,000
P50 · FY2020 · CA · contact PI
Developmental Research Program$68,666
P50 · FY2020 · CA · contact PI
Career Enhancement Program$68,666
P50 · FY2020 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$917,850
P50 · FY2019 · CA
Harnessing the power of exosomes for non-coding RNA delivery$633,104
R35 · FY2019 · CA · contact PI
Platelets promote growth of ovarian cancer$504,165
R01 · FY2019 · CA
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$457,671
R01 · FY2019 · CA
Training of Academic Gynecologic Oncologists$437,175
T32 · FY2019 · CA
P3: EphA2 Targeting in Uterine Carcinoma$290,151
P50 · FY2019 · CA · contact PI
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer$258,492
P50 · FY2019 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,813,624
P50 · FY2018 · CA
Harnessing the power of exosomes for non-coding RNA delivery$905,873
R35 · FY2018 · CA · contact PI
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer$485,829
R01 · FY2018 · CA
Training of Academic Gynecologic Oncologists$467,856
T32 · FY2018 · CA
P3: EphA2 Targeting in Uterine Carcinoma$291,692
P50 · FY2018 · CA · contact PI
Developmental Research Program$80,000
P50 · FY2018 · CA · contact PI
Career Enhancement Program$80,000
P50 · FY2018 · CA · contact PI
P3: EphA2 Targeting in Uterine Carcinoma$17,454
P50 · FY2018 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,732,856
P50 · FY2017 · CA
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$1,000,000
UH3 · FY2017 · TR · contact PI
Harnessing the power of exosomes for non-coding RNA delivery$704,789
R35 · FY2017 · CA · contact PI
Training of Academic Gynecologic Oncologists$468,471
T32 · FY2017 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$356,980
R01 · FY2017 · CA · contact PI
Platelets promote growth of ovarian cancer$332,000
R01 · FY2017 · CA
P3: EphA2 Targeting in Uterine Carcinoma$311,990
P50 · FY2017 · CA · contact PI
Career Enhancement Program$76,000
P50 · FY2017 · CA · contact PI
Developmental Research Program$76,000
P50 · FY2017 · CA · contact PI
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$1,000,000
UH3 · FY2016 · TR · contact PI
Training of Academic Gynecologic Oncologists$466,239
T32 · FY2016 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$356,980
R01 · FY2016 · CA · contact PI
Platelets promote growth of ovarian cancer$332,000
R01 · FY2016 · CA
P3: EphA2 Targeting in Uterine Carcinoma$295,325
P50 · FY2016 · CA · contact PI
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$80,000
UH3 · FY2016 · TR · contact PI
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$999,500
UH3 · FY2015 · TR · contact PI
Training of Academic Gynecologic Oncologists$401,193
T32 · FY2015 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$359,706
R01 · FY2015 · CA · contact PI
Platelets promote growth of ovarian cancer$332,000
R01 · FY2015 · CA
In Vivo Assessment of Localized Magnetic Fluid Hyperthermia for Ovarian Cancer$89,694
U54 · FY2015 · CA · contact PI
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$79,168
UH3 · FY2015 · TR · contact PI
Texas Center for Cancer Nanomedicine$2,695,386
U54 · FY2014 · CA
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$500,000
UH2 · FY2014 · TR · contact PI
Training of Academic Gynecologic Oncologists$407,137
T32 · FY2014 · CA
Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature$402,282
U54 · FY2014 · CA · contact PI
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$384,255
R01 · FY2014 · CA · contact PI
Platelets promote growth of ovarian cancer$322,040
R01 · FY2014 · CA
EphA2 Targeting in Uterine Carcinoma$183,553
P50 · FY2014 · CA · contact PI
P2 - Targeting DII4-Notch Signaling in Ovarian Cancer$182,671
P50 · FY2014 · CA · contact PI
In Vivo Assessment of Localized Magnetic Fluid Hyperthermia for Ovarian Cancer$90,187
U54 · FY2014 · CA · contact PI
HPV Communication to Microenvironment via Exosomes$80,000
UH2 · FY2014 · TR · contact PI
Texas Center for Cancer Nanomedicine$1,850,049
U54 · FY2013 · CA
Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature$542,871
U54 · FY2013 · CA · contact PI
Novel extra cellular RNA-based combinatorial RNA inhibition therapy$500,000
UH2 · FY2013 · TR · contact PI
Training of Academic Gynecologic Oncologists$392,980
T32 · FY2013 · CA
Platelets promote growth of ovarian cancer$332,000
R01 · FY2013 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$297,324
R01 · FY2013 · CA · contact PI
EphA2 Targeting in Uterine Carcinoma$258,825
P50 · FY2013 · CA · contact PI
P2 - Targeting DII4-Notch Signaling in Ovarian Cancer$252,969
P50 · FY2013 · CA · contact PI
In Vivo Assessment of Localized Magnetic Fluid Hyperthermia for Ovarian Cancer$91,854
U54 · FY2013 · CA · contact PI
Texas Center for Cancer Nanomedicine$2,538,514
U54 · FY2012 · CA
Training of Academic Gynecologic Oncologists$391,105
T32 · FY2012 · CA
Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature$366,609
U54 · FY2012 · CA · contact PI
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$322,654
R01 · FY2012 · CA · contact PI
P2 - Targeting DII4-Notch Signaling in Ovarian Cancer$207,175
P50 · FY2012 · CA · contact PI
EphA2 Targeting in Uterine Carcinoma$196,871
P50 · FY2012 · CA · contact PI
Texas Center for Cancer Nanomedicine$2,579,927
U54 · FY2011 · CA
New Reagents for Synthesis of High Potency siRNA$475,210
R44 · FY2011 · GM
Training of Academic Gynecologic Oncologists$352,110
T32 · FY2011 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$338,690
R01 · FY2011 · CA · contact PI
Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature$327,795
U54 · FY2011 · CA · contact PI
P2 - Targeting DII4-Notch Signaling in Ovarian Cancer$195,270
P50 · FY2011 · CA · contact PI
EphA2 Targeting in Uterine Carcinoma$184,056
P50 · FY2011 · CA · contact PI
OVARIAN CANCER PLATELETS$36,793
P41 · FY2011 · RR · contact PI
Texas Center for Cancer Nanomedicine$2,735,267
U54 · FY2010 · CA
Subcellular localization of nanoparticles$993,315
RC2 · FY2010 · GM
Subcellular localization of nanoparticles$495,098
RC2 · FY2010 · GM
New Reagents for Synthesis of High Potency siRNA$474,025
R44 · FY2010 · GM
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$358,839
R01 · FY2010 · CA · contact PI
Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature$339,218
U54 · FY2010 · CA · contact PI
P2 - Targeting DII4-Notch Signaling in Ovarian Cancer$199,352
P50 · FY2010 · CA · contact PI
EphA2 Targeting in Uterine Carcinoma$189,134
P50 · FY2010 · CA · contact PI
OVARIAN CANCER PLATELETS$4,300
P41 · FY2010 · RR · contact PI
Subcellular localization of nanoparticles$1,513,417
RC2 · FY2009 · GM
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$381,050
R01 · FY2009 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$308,380
R01 · FY2009 · CA · contact PI
Cell-specific Targeting of Ovarian Cancer Vasculature$266,949
P50 · FY2009 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$329,472
R01 · FY2008 · CA · contact PI
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$271,595
R01 · FY2008 · CA · contact PI
Cell-specific Targeting of Ovarian Cancer Vasculature$186,960
P50 · FY2008 · CA · contact PI
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$413,434
R01 · FY2007 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$329,855
R01 · FY2007 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$357,859
R01 · FY2006 · CA · contact PI
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$295,970
R01 · FY2006 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$48,977
R01 · FY2006 · CA · contact PI
Tumor metastasis: Biobehavioral mechanisms$398,560
R01 · FY2005 · CA
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation$335,290
R01 · FY2005 · CA
Tumor metastasis: Biobehavioral mechanisms$330,598
R01 · FY2004 · CA
ANORECTAL MANOMETRY TO ASSCESS RECTAL DYSFUNCTION FOLLOWING HYSTERECTOMY$22,028
M01 · FY2000 · RR